NYSEAMERICAN:SER Serina Therapeutics (SER) Stock Price, News & Analysis $2.35 -0.10 (-4.08%) Closing price 09/15/2026 04:10 PM EasternExtended Trading$2.36 +0.00 (+0.21%) As of 09/15/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Serina Therapeutics Stock (NYSEAMERICAN:SER) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Serina Therapeutics alerts:Sign Up Key Stats Today's Range$2.25▼$2.4750-Day Range$1.95▼$2.8752-Week Range$1.22▼$5.83Volume31,675 shsAverage Volume62,408 shsMarket Capitalization$59.69 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company Overview Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama. Read More Serina Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreSER MarketRank™: Serina Therapeutics scored higher than 76% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingSerina Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialSerina Therapeutics has a consensus price target of $8.00, representing about 240.4% upside from its current price of $2.35.Amount of Analyst CoverageSerina Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Serina Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Serina Therapeutics is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Serina Therapeutics is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.34% of the float of Serina Therapeutics has been sold short.Short Interest Ratio / Days to CoverSerina Therapeutics has a short interest ratio ("days to cover") of 1.32, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Serina Therapeutics has recently decreased by 51.84%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSerina Therapeutics does not currently pay a dividend.Dividend GrowthSerina Therapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.35 News SentimentSerina Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Serina Therapeutics this week, compared to 1 article on an average week.Search Interest8 people have searched for SER on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Serina Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $2,030.00 in company stock, which represents 0.0034% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Serina Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,030.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.70% of the stock of Serina Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions12.50% of the stock of Serina Therapeutics is held by institutions.Read more about Serina Therapeutics' insider trading history. Receive SER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Serina Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SER Stock News HeadlinesSerina Therapeutics, Inc. (NYSEAMERICAN:SER) Sees Significant Decline in Short InterestSeptember 14 at 4:22 AM | americanbankingnews.comBTIG Research Reiterates "Buy" Rating for Serina Therapeutics (NYSEAMERICAN:SER)September 12, 2026 | americanbankingnews.comWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax that year in exchange for potential tax-free qualified growth later. Key questions remain: how much to convert, where the tax payment comes from, and whether this years income leaves room. Roth IRAs also avoid lifetime required minimum distributions. A fiduciary financial advisor can help size a conversion around your specific tax situation and goals.September 16 at 1:00 AM | SmartAsset (Ad)Serina Therapeutics op H.C. Wainwright-conferentie: vooruitgang in Parkinson-programmaSeptember 11, 2026 | nl.investing.comSerina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | globenewswire.comSerina Reports Positive Cohort 1 Data For Phase 1 Evaluating Parkinson's TherapySeptember 9, 2026 | rttnews.comSerina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2September 9, 2026 | finance.yahoo.comSerina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2September 9, 2026 | globenewswire.comSee More Headlines SER Stock Analysis - Frequently Asked Questions How have SER shares performed this year? Serina Therapeutics' stock was trading at $2.87 on January 20, 2026. Since then, SER shares have decreased by 18.1% and is now trading at $2.35. How were Serina Therapeutics' earnings last quarter? Serina Therapeutics, Inc. (NYSEAMERICAN:SER) released its quarterly earnings results on Thursday, August, 13th. The company reported ($0.55) earnings per share (EPS) for the quarter. How do I buy shares of Serina Therapeutics? Shares of SER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today9/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SER's financial health is in the Green zone, according to TradeSmith. SER has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:SER CIK1708599 Webserinatherapeutics.com Phone(256) 327-9630Fax510-671-8619EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Serina Therapeutics$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside+240.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.18 million Net MarginsN/A Pretax Margin-16,358.46% Return on Equity-416.40% Return on Assets-132.69% Debt Debt-to-Equity Ratio0.16 Current Ratio6.65 Quick Ratio6.65 Sales & Book Value Annual Sales$130 thousand Price / Sales459.15 Cash FlowN/A Price / Cash FlowN/A Book Value($0.46) per share Price / Book-5.11Miscellaneous Outstanding Shares25,400,000Free Float20,904,000Market Cap$59.69 million OptionableN/A Beta1.18 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSEAMERICAN:SER) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersThis Microcap Is Taking On the Energy Industry’s Dirtiest ProblemsA small company has developed water-based cleaning technologies aimed at some of heavy industry's toughest pro...Wall Street Logic | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...US Gold Bureau | SponsoredJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Serina Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Serina Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
